FR2727016B1 - Compositions pharmaceutiques a base d'ondansetron - Google Patents

Compositions pharmaceutiques a base d'ondansetron

Info

Publication number
FR2727016B1
FR2727016B1 FR9513723A FR9513723A FR2727016B1 FR 2727016 B1 FR2727016 B1 FR 2727016B1 FR 9513723 A FR9513723 A FR 9513723A FR 9513723 A FR9513723 A FR 9513723A FR 2727016 B1 FR2727016 B1 FR 2727016B1
Authority
FR
France
Prior art keywords
ondansetron
pharmaceutical compositions
based pharmaceutical
pharmaceutically acceptable
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9513723A
Other languages
English (en)
Other versions
FR2727016A1 (fr
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Inc
Original Assignee
Glaxo Wellcome Inc Canada
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2727016(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc Canada, Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc Canada
Publication of FR2727016A1 publication Critical patent/FR2727016A1/fr
Application granted granted Critical
Publication of FR2727016B1 publication Critical patent/FR2727016B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR9513723A 1994-11-22 1995-11-20 Compositions pharmaceutiques a base d'ondansetron Expired - Lifetime FR2727016B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (2)

Publication Number Publication Date
FR2727016A1 FR2727016A1 (fr) 1996-05-24
FR2727016B1 true FR2727016B1 (fr) 1998-04-03

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513723A Expired - Lifetime FR2727016B1 (fr) 1994-11-22 1995-11-20 Compositions pharmaceutiques a base d'ondansetron

Country Status (31)

Country Link
US (2) US5955488A (fr)
EP (1) EP0793495B1 (fr)
JP (1) JP3001264B2 (fr)
KR (1) KR970706814A (fr)
CN (1) CN1080118C (fr)
AT (1) ATE193444T1 (fr)
AU (1) AU704160B2 (fr)
BE (1) BE1010250A3 (fr)
BR (1) BR9509808A (fr)
CY (1) CY2166B1 (fr)
CZ (1) CZ285250B6 (fr)
DE (1) DE69517332T2 (fr)
DK (1) DK0793495T3 (fr)
ES (1) ES2147309T3 (fr)
FI (1) FI119355B (fr)
FR (1) FR2727016B1 (fr)
GB (2) GB9423511D0 (fr)
GR (1) GR3033937T3 (fr)
HK (1) HK1009591A1 (fr)
HU (1) HU226891B1 (fr)
IL (1) IL116084A (fr)
IT (1) IT1282352B1 (fr)
MX (1) MX9703735A (fr)
NO (1) NO306893B1 (fr)
NZ (1) NZ296982A (fr)
PL (1) PL181179B1 (fr)
PT (1) PT793495E (fr)
RU (1) RU2159614C2 (fr)
TW (1) TW398976B (fr)
WO (1) WO1996015785A1 (fr)
ZA (1) ZA959821B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
DE69738333T2 (de) * 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
DE60024491T2 (de) * 1999-12-01 2006-08-10 Natco Pharma Ltd., Banjara Hills Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
SK6182003A3 (en) * 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
DE20320528U1 (de) * 2002-04-30 2004-09-16 Teva Pharmaceuticals Usa, Inc. Neue Kristallformen von Ondansetron und Arzneimittel, welche die neuen Formen enthalten
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
WO2004045615A1 (fr) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Methode pour traiter les vomissements
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
AU2004283832B2 (en) * 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
EP2168975A3 (fr) * 2004-05-24 2012-01-11 Genvault Corporation Méthode pour le stockage stable des molécules biologiques sous forme récupérable
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (fr) * 2005-08-17 2008-05-14 Synthon B.V. Procede de fabrication d'olanzapine de forme i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
WO2007107297A1 (fr) * 2006-03-17 2007-09-27 Synthon B.V. Sel d'amantadine de montélukast
WO2007134845A2 (fr) * 2006-05-18 2007-11-29 Synthon B.V. Composition pharmaceutique d'olanzapine
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
EP2124556B1 (fr) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Compositions pharmaceutiques
SI1940366T1 (sl) * 2006-10-24 2009-08-31 Helsinn Healthcare Sa Mehke kapsule, ki obsegajo palonosetron hidroklorid, z izboljšano stabilnostjo in biorazpoložljivostjo
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
EP3090743A1 (fr) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2253316B1 (fr) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur 5-HT3 de la sérotonine pour une utilisation dans le traitement ou la prévention d'une pathologie de l'oreille interne avec déficits vestibulaires
PL2432467T3 (pl) * 2009-05-20 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Zastosowanie antagonistów receptora 5-ht3 serotoniny w leczeniu zaburzeń przedsionkowych ze zmianami chorobowymi
EP3311667A1 (fr) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Compositions pharmaceutiques
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
MA44660A (fr) 2016-04-14 2019-02-20 Sensorion (+)-azasetron destiné à être utilisé dans le traitement de troubles de l'oreille

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE24964T1 (de) * 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
PL320295A1 (en) 1997-09-15
GB2295318A (en) 1996-05-29
NZ296982A (en) 1998-06-26
FI972167A0 (fi) 1997-05-21
ATE193444T1 (de) 2000-06-15
BE1010250A3 (fr) 1998-04-07
EP0793495A1 (fr) 1997-09-10
MX9703735A (es) 1998-07-31
GB2295318B (en) 1998-10-28
IT1282352B1 (it) 1998-03-20
DE69517332D1 (de) 2000-07-06
WO1996015785A1 (fr) 1996-05-30
BR9509808A (pt) 1997-10-21
FR2727016A1 (fr) 1996-05-24
AU4173996A (en) 1996-06-17
CN1080118C (zh) 2002-03-06
PL181179B1 (pl) 2001-06-29
NO972325D0 (no) 1997-05-21
TW398976B (en) 2000-07-21
ITRM950762A0 (fr) 1995-11-20
FI972167A (fi) 1997-05-21
GB9423511D0 (en) 1995-01-11
JPH10508864A (ja) 1998-09-02
US6063802A (en) 2000-05-16
RU2159614C2 (ru) 2000-11-27
US5955488A (en) 1999-09-21
DK0793495T3 (da) 2000-10-09
KR970706814A (ko) 1997-12-01
HU226891B1 (en) 2010-01-28
CY2166B1 (en) 2002-08-23
GR3033937T3 (en) 2000-11-30
EP0793495B1 (fr) 2000-05-31
IL116084A (en) 2000-01-31
DE69517332T2 (de) 2000-11-30
HK1009591A1 (en) 1999-06-04
ZA959821B (en) 1996-07-31
FI119355B (fi) 2008-10-31
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
NO972325L (no) 1997-05-22
CZ154997A3 (en) 1997-10-15
PT793495E (pt) 2000-10-31
ES2147309T3 (es) 2000-09-01
HUT77886A (hu) 1998-09-28
IL116084A0 (en) 1996-01-31
JP3001264B2 (ja) 2000-01-24
GB9523667D0 (en) 1996-01-24
AU704160B2 (en) 1999-04-15
NO306893B1 (no) 2000-01-10
CZ285250B6 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
AP1637A (en) Celecoxib compositions.
MY138227A (en) Valdecoxib compositions
MY118371A (en) Tetrahydrolipstatin containing compositions
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
CA2205600A1 (fr) Compositions d'ondansetron lyophilisees
ES2133052A1 (es) Nuevas formulaciones farmaceuticas liquidas para la via oral.

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: GLAXOSMITHKLINE INC., CA

Effective date: 20150109